 |
| Dr. Ashraf Dallol |
|
 |
Assistant Professor
Coordinator of High-Throughput Sequencing Service Units
Assistant of Bioinformatics Service Unit
Genomic Screening and Cancer Research Groups
Dr Dallol has over 10 years of post-doctoral experience with emphasis on cancer research utilizing genetic and epigenetic up-to-date technologies and approaches. His enthusiasm for research and hard work has resulted in accumulating over 30 high-quality publications that is cited over 1000 times and with an H-Index of 17. His multidisciplinary approach has put him in a position to oversee the epigenetic profiling of cancer as well as elucidating the molecular mechanisms underlying congenital hearing loss in the Kingdom of Saudi Arabia.
Since his arrival at the CEGMR, he played a pivotal role in establishing the hearing loss program and established very useful collaborations to build up representative cohort of samples. This work has resulted in a publication in an international journal and research grants of two research proposals totaling an approximately 4,500,000 SAR. His current research utilizes next-generation sequencing technology to perform whole-genome sequencing, whole-exome sequencing and genome-wide methylation analysis. Dr Dallol has co-founded a new 50,000,000 SAR research center at King Abdulaziz University to utilize the power of high-throughput sequencing in the delivery of Personalized Medicine to the people of Jeddah.
Selected Publications:
1. High fibroblast growth factor 19 (FGF19) expression predicts worse prognosis in invasive ductal carcinoma of breast.
Buhmeida A, Dallol A, Merdad A, Al-Maghrabi J, Gari MA, Abu-Elmagd MM, Chaudhary AG, Abuzenadah AM, Nedjadi T, Ermiah E, Al-Thubaity F, Al-Qahtani MH.
Tumour Biol. 2014 Mar;35(3) :2817-24. doi: 10.1007/s13277-013-1374-y. Epub 2013 Nov 19.
2. Functional epigenetic approach identifies frequently methylated genes in Ewing sarcoma.
Alholle A, Brini AT, Gharanei S, Vaiyapuri S, Arrigoni E, Dallol A, Gentle D, Kishida T, Hiruma T, Avigad S, Grimer R, Maher ER, Latif F.
Epigenetics. 2013 Nov;8(11):1198-204. doi: 10.4161/epi.26266. Epub 2013 Sep 4.
3. RASSF2 methylation is a strong prognostic marker in younger age patients with Ewing sarcoma.
Gharanei S, Brini AT, Vaiyapuri S, Alholle A, Dallol A, Arrigoni E, Kishida T, Hiruma T, Avigad S, Grimer R, Maher ER, Latif F.
Epigenetics. 2013 Sep;8(9):893-8. doi: 10.4161/epi.25617. Epub 2013 Jul 18.
4. Methylation of the polycomb group target genes is a possible biomarker for favorable prognosis in colorectal cancer.
Dallol A, Al-Maghrabi J, Buhmeida A, Gari MA, Chaudhary AG, Schulten HJ, Abuzenadah AM, Al-Ahwal MS, Sibiany A, Al-Qahtani MH.
Cancer Epidemiol Biomarkers Prev. 2012 Nov;21(11):2069-75. doi: 10.1158/1055-9965.EPI-12-0755. Epub 2012 Sep 25.
|